Intravenous iron versus oral iron versus no iron with or without erythropoiesis- stimulating agents (ESA) for cancer patients with anaemia: a systematic review and network meta-analysis.
Journal
The Cochrane database of systematic reviews
ISSN: 1469-493X
Titre abrégé: Cochrane Database Syst Rev
Pays: England
ID NLM: 100909747
Informations de publication
Date de publication:
20 06 2022
20 06 2022
Historique:
entrez:
20
6
2022
pubmed:
21
6
2022
medline:
23
6
2022
Statut:
epublish
Résumé
Anaemia is common among cancer patients and they may require red blood cell transfusions. Erythropoiesis-stimulating agents (ESAs) and iron might help in reducing the need for red blood cell transfusions. However, it remains unclear whether the combination of both drugs is preferable compared to using one drug. To systematically review the effect of intravenous iron, oral iron or no iron in combination with or without ESAs to prevent or alleviate anaemia in cancer patients and to generate treatment rankings using network meta-analyses (NMAs). We identified studies by searching bibliographic databases (CENTRAL, MEDLINE, Embase; until June 2021). We also searched various registries, conference proceedings and reference lists of identified trials. We included randomised controlled trials comparing intravenous, oral or no iron, with or without ESAs for the prevention or alleviation of anaemia resulting from chemotherapy, radiotherapy, combination therapy or the underlying malignancy in cancer patients. Two review authors independently extracted data and assessed risk of bias. Outcomes were on-study mortality, number of patients receiving red blood cell transfusions, number of red blood cell units, haematological response, overall mortality and adverse events. We conducted NMAs and generated treatment rankings. We assessed the certainty of the evidence using GRADE. Ninety-six trials (25,157 participants) fulfilled our inclusion criteria; 62 trials (24,603 participants) could be considered in the NMA (12 different treatment options). Here we present the comparisons of ESA with or without iron and iron alone versus no treatment. Further results and subgroup analyses are described in the full text. On-study mortality We estimated that 92 of 1000 participants without treatment for anaemia died up to 30 days after the active study period. Evidence from NMA (55 trials; 15,074 participants) suggests that treatment with ESA and intravenous iron (12 of 1000; risk ratio (RR) 0.13, 95% confidence interval (CI) 0.01 to 2.29; low certainty) or oral iron (34 of 1000; RR 0.37, 95% CI 0.01 to 27.38; low certainty) may decrease or increase and ESA alone (103 of 1000; RR 1.12, 95% CI 0.92 to 1.35; moderate certainty) probably slightly increases on-study mortality. Additionally, treatment with intravenous iron alone (271 of 1000; RR 2.95, 95% CI 0.71 to 12.34; low certainty) may increase and oral iron alone (24 of 1000; RR 0.26, 95% CI 0.00 to 19.73; low certainty) may increase or decrease on-study mortality. Haematological response We estimated that 90 of 1000 participants without treatment for anaemia had a haematological response. Evidence from NMA (31 trials; 6985 participants) suggests that treatment with ESA and intravenous iron (604 of 1000; RR 6.71, 95% CI 4.93 to 9.14; moderate certainty), ESA and oral iron (527 of 1000; RR 5.85, 95% CI 4.06 to 8.42; moderate certainty), and ESA alone (467 of 1000; RR 5.19, 95% CI 4.02 to 6.71; moderate certainty) probably increases haematological response. Additionally, treatment with oral iron alone may increase haematological response (153 of 1000; RR 1.70, 95% CI 0.69 to 4.20; low certainty). Red blood cell transfusions We estimated that 360 of 1000 participants without treatment for anaemia needed at least one transfusion. Evidence from NMA (69 trials; 18,684 participants) suggests that treatment with ESA and intravenous iron (158 of 1000; RR 0.44, 95% CI 0.31 to 0.63; moderate certainty), ESA and oral iron (144 of 1000; RR 0.40, 95% CI 0.24 to 0.66; moderate certainty) and ESA alone (212 of 1000; RR 0.59, 95% CI 0.51 to 0.69; moderate certainty) probably decreases the need for transfusions. Additionally, treatment with intravenous iron alone (268 of 1000; RR 0.74, 95% CI 0.43 to 1.28; low certainty) and with oral iron alone (333 of 1000; RR 0.92, 95% CI 0.54 to 1.57; low certainty) may decrease or increase the need for transfusions. Overall mortality We estimated that 347 of 1000 participants without treatment for anaemia died overall. Low-certainty evidence from NMA (71 trials; 21,576 participants) suggests that treatment with ESA and intravenous iron (507 of 1000; RR 1.46, 95% CI 0.87 to 2.43) or oral iron (482 of 1000; RR 1.39, 95% CI 0.60 to 3.22) and intravenous iron alone (521 of 1000; RR 1.50, 95% CI 0.63 to 3.56) or oral iron alone (534 of 1000; RR 1.54, 95% CI 0.66 to 3.56) may decrease or increase overall mortality. Treatment with ESA alone may lead to little or no difference in overall mortality (357 of 1000; RR 1.03, 95% CI 0.97 to 1.10; low certainty). Thromboembolic events We estimated that 36 of 1000 participants without treatment for anaemia developed thromboembolic events. Evidence from NMA (50 trials; 15,408 participants) suggests that treatment with ESA and intravenous iron (66 of 1000; RR 1.82, 95% CI 0.98 to 3.41; moderate certainty) probably slightly increases and with ESA alone (66 of 1000; RR 1.82, 95% CI 1.34 to 2.47; high certainty) slightly increases the number of thromboembolic events. None of the trials reported results on the other comparisons. Thrombocytopenia or haemorrhage We estimated that 76 of 1000 participants without treatment for anaemia developed thrombocytopenia/haemorrhage. Evidence from NMA (13 trials, 2744 participants) suggests that treatment with ESA alone probably leads to little or no difference in thrombocytopenia/haemorrhage (76 of 1000; RR 1.00, 95% CI 0.67 to 1.48; moderate certainty). None of the trials reported results on other comparisons. Hypertension We estimated that 10 of 1000 participants without treatment for anaemia developed hypertension. Evidence from NMA (24 trials; 8383 participants) suggests that treatment with ESA alone probably increases the number of hypertensions (29 of 1000; RR 2.93, 95% CI 1.19 to 7.25; moderate certainty). None of the trials reported results on the other comparisons. When considering ESAs with iron as prevention for anaemia, one has to balance between efficacy and safety. Results suggest that treatment with ESA and iron probably decreases number of blood transfusions, but may increase mortality and the number of thromboembolic events. For most outcomes the different comparisons within the network were not fully connected, so ranking of all treatments together was not possible. More head-to-head comparisons including all evaluated treatment combinations are needed to fill the gaps and prove results of this review.
Sections du résumé
BACKGROUND
Anaemia is common among cancer patients and they may require red blood cell transfusions. Erythropoiesis-stimulating agents (ESAs) and iron might help in reducing the need for red blood cell transfusions. However, it remains unclear whether the combination of both drugs is preferable compared to using one drug.
OBJECTIVES
To systematically review the effect of intravenous iron, oral iron or no iron in combination with or without ESAs to prevent or alleviate anaemia in cancer patients and to generate treatment rankings using network meta-analyses (NMAs).
SEARCH METHODS
We identified studies by searching bibliographic databases (CENTRAL, MEDLINE, Embase; until June 2021). We also searched various registries, conference proceedings and reference lists of identified trials.
SELECTION CRITERIA
We included randomised controlled trials comparing intravenous, oral or no iron, with or without ESAs for the prevention or alleviation of anaemia resulting from chemotherapy, radiotherapy, combination therapy or the underlying malignancy in cancer patients.
DATA COLLECTION AND ANALYSIS
Two review authors independently extracted data and assessed risk of bias. Outcomes were on-study mortality, number of patients receiving red blood cell transfusions, number of red blood cell units, haematological response, overall mortality and adverse events. We conducted NMAs and generated treatment rankings. We assessed the certainty of the evidence using GRADE.
MAIN RESULTS
Ninety-six trials (25,157 participants) fulfilled our inclusion criteria; 62 trials (24,603 participants) could be considered in the NMA (12 different treatment options). Here we present the comparisons of ESA with or without iron and iron alone versus no treatment. Further results and subgroup analyses are described in the full text. On-study mortality We estimated that 92 of 1000 participants without treatment for anaemia died up to 30 days after the active study period. Evidence from NMA (55 trials; 15,074 participants) suggests that treatment with ESA and intravenous iron (12 of 1000; risk ratio (RR) 0.13, 95% confidence interval (CI) 0.01 to 2.29; low certainty) or oral iron (34 of 1000; RR 0.37, 95% CI 0.01 to 27.38; low certainty) may decrease or increase and ESA alone (103 of 1000; RR 1.12, 95% CI 0.92 to 1.35; moderate certainty) probably slightly increases on-study mortality. Additionally, treatment with intravenous iron alone (271 of 1000; RR 2.95, 95% CI 0.71 to 12.34; low certainty) may increase and oral iron alone (24 of 1000; RR 0.26, 95% CI 0.00 to 19.73; low certainty) may increase or decrease on-study mortality. Haematological response We estimated that 90 of 1000 participants without treatment for anaemia had a haematological response. Evidence from NMA (31 trials; 6985 participants) suggests that treatment with ESA and intravenous iron (604 of 1000; RR 6.71, 95% CI 4.93 to 9.14; moderate certainty), ESA and oral iron (527 of 1000; RR 5.85, 95% CI 4.06 to 8.42; moderate certainty), and ESA alone (467 of 1000; RR 5.19, 95% CI 4.02 to 6.71; moderate certainty) probably increases haematological response. Additionally, treatment with oral iron alone may increase haematological response (153 of 1000; RR 1.70, 95% CI 0.69 to 4.20; low certainty). Red blood cell transfusions We estimated that 360 of 1000 participants without treatment for anaemia needed at least one transfusion. Evidence from NMA (69 trials; 18,684 participants) suggests that treatment with ESA and intravenous iron (158 of 1000; RR 0.44, 95% CI 0.31 to 0.63; moderate certainty), ESA and oral iron (144 of 1000; RR 0.40, 95% CI 0.24 to 0.66; moderate certainty) and ESA alone (212 of 1000; RR 0.59, 95% CI 0.51 to 0.69; moderate certainty) probably decreases the need for transfusions. Additionally, treatment with intravenous iron alone (268 of 1000; RR 0.74, 95% CI 0.43 to 1.28; low certainty) and with oral iron alone (333 of 1000; RR 0.92, 95% CI 0.54 to 1.57; low certainty) may decrease or increase the need for transfusions. Overall mortality We estimated that 347 of 1000 participants without treatment for anaemia died overall. Low-certainty evidence from NMA (71 trials; 21,576 participants) suggests that treatment with ESA and intravenous iron (507 of 1000; RR 1.46, 95% CI 0.87 to 2.43) or oral iron (482 of 1000; RR 1.39, 95% CI 0.60 to 3.22) and intravenous iron alone (521 of 1000; RR 1.50, 95% CI 0.63 to 3.56) or oral iron alone (534 of 1000; RR 1.54, 95% CI 0.66 to 3.56) may decrease or increase overall mortality. Treatment with ESA alone may lead to little or no difference in overall mortality (357 of 1000; RR 1.03, 95% CI 0.97 to 1.10; low certainty). Thromboembolic events We estimated that 36 of 1000 participants without treatment for anaemia developed thromboembolic events. Evidence from NMA (50 trials; 15,408 participants) suggests that treatment with ESA and intravenous iron (66 of 1000; RR 1.82, 95% CI 0.98 to 3.41; moderate certainty) probably slightly increases and with ESA alone (66 of 1000; RR 1.82, 95% CI 1.34 to 2.47; high certainty) slightly increases the number of thromboembolic events. None of the trials reported results on the other comparisons. Thrombocytopenia or haemorrhage We estimated that 76 of 1000 participants without treatment for anaemia developed thrombocytopenia/haemorrhage. Evidence from NMA (13 trials, 2744 participants) suggests that treatment with ESA alone probably leads to little or no difference in thrombocytopenia/haemorrhage (76 of 1000; RR 1.00, 95% CI 0.67 to 1.48; moderate certainty). None of the trials reported results on other comparisons. Hypertension We estimated that 10 of 1000 participants without treatment for anaemia developed hypertension. Evidence from NMA (24 trials; 8383 participants) suggests that treatment with ESA alone probably increases the number of hypertensions (29 of 1000; RR 2.93, 95% CI 1.19 to 7.25; moderate certainty). None of the trials reported results on the other comparisons.
AUTHORS' CONCLUSIONS
When considering ESAs with iron as prevention for anaemia, one has to balance between efficacy and safety. Results suggest that treatment with ESA and iron probably decreases number of blood transfusions, but may increase mortality and the number of thromboembolic events. For most outcomes the different comparisons within the network were not fully connected, so ranking of all treatments together was not possible. More head-to-head comparisons including all evaluated treatment combinations are needed to fill the gaps and prove results of this review.
Identifiants
pubmed: 35724934
doi: 10.1002/14651858.CD012633.pub2
pmc: PMC9208863
doi:
Substances chimiques
Hematinics
0
Iron
E1UOL152H7
Types de publication
Journal Article
Meta-Analysis
Review
Systematic Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
CD012633Informations de copyright
Copyright © 2022 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Références
J Clin Oncol. 2009 Dec 1;27(34):5751-6
pubmed: 19884550
Pharmacoeconomics. 2003;21(16):1153-69
pubmed: 14594437
Oncologist. 2007 Jun;12(6):727-37
pubmed: 17602062
J Clin Oncol. 2005 Apr 20;23(12):2606-17
pubmed: 15452187
Br J Haematol. 1998 Dec;103(4):1070-4
pubmed: 9886322
Stat Med. 2014 Nov 10;33(25):4353-69
pubmed: 24942211
Cochrane Database Syst Rev. 2009 Jul 08;(3):CD007303
pubmed: 19588423
Med Oncol. 2014 Dec;31(12):302
pubmed: 25373320
Oncologist. 2006 Feb;11(2):197-205
pubmed: 16476840
J Clin Oncol. 1997 Jul;15(7):2715-21
pubmed: 9215845
Am J Hematol. 2021 Dec 1;96(12):1639-1646
pubmed: 34653287
J Clin Epidemiol. 2019 Aug;112:12-19
pubmed: 30986533
Br J Haematol. 2002 Oct;119(1):79-86
pubmed: 12358906
Br J Cancer. 2002 Dec 2;87(12):1341-53
pubmed: 12454760
Am J Kidney Dis. 2001 Apr;37(4):743-9
pubmed: 11273874
Ann Oncol. 2009 Jun;20(6):1105-12
pubmed: 19174452
Eur J Cancer. 2003 Sep;39(14):2026-34
pubmed: 12957457
Leuk Lymphoma. 2016;57(3):596-603
pubmed: 26293380
Br J Cancer. 2011 Oct 25;105(9):1267-72
pubmed: 21959870
Am J Med. 2004 Apr 5;116 Suppl 7A:11S-26S
pubmed: 15050883
J Clin Oncol. 2006 Aug 1;24(22):3583-9
pubmed: 16877725
Cochrane Database Syst Rev. 2016 Feb 04;2:CD009624
pubmed: 26845108
Radiother Oncol. 1999 Feb;50(2):185-90
pubmed: 10368042
Cancer J Sci Am. 1995 Nov-Dec;1(4):252-60
pubmed: 9166485
Br J Haematol. 2005 Apr;129(2):206-9
pubmed: 15813848
Ann Oncol. 2010 May;21 Suppl 5:v244-7
pubmed: 20555090
Cochrane Database Syst Rev. 2012 Dec 12;12:CD003407
pubmed: 23235597
J Palliat Med. 2009 Jan;12(1):60-3
pubmed: 19284264
J Clin Oncol. 2008 Mar 1;26(7):1040-50
pubmed: 18227526
Oncologist. 2010;15(8):894-902
pubmed: 20647390
BMJ Open. 2016 Oct 7;6(10):e012231
pubmed: 27855097
Semin Oncol. 2001 Apr;28(2 Suppl 8):7-14
pubmed: 11395846
Med Decis Making. 2013 Jul;33(5):641-56
pubmed: 23804508
Haematologica. 2016 Aug;101(8):918-25
pubmed: 27229713
Ann Oncol. 1998 Mar;9(3):255-60
pubmed: 9602258
Cancer Biol Ther. 2009 Jan;8(1):13-7
pubmed: 18981719
Eur J Cancer. 1993;29A Suppl 2:S2-8
pubmed: 8398361
BMC Med Res Methodol. 2013 Mar 09;13:35
pubmed: 23496991
Cancer. 2012 Feb 1;118(3):848-55
pubmed: 21751205
J Clin Oncol. 2008 Apr 1;26(10):1611-8
pubmed: 18375890
J BUON. 2003 Apr-Jun;8(2):127-32
pubmed: 17472238
J Clin Oncol. 2011 Oct 1;29(28):3791-7
pubmed: 21860000
Br J Cancer. 1998 Jun;77(11):1996-2002
pubmed: 9667681
Trials. 2007 Jun 07;8:16
pubmed: 17555582
J Pediatr Gastroenterol Nutr. 2002 Mar;34(3):286-90
pubmed: 11964953
Oncologist. 2010;15(9):935-43
pubmed: 20798194
Oncologist. 2007 Feb;12(2):231-42
pubmed: 17296819
Oncology. 2003;64(2):102-10
pubmed: 12566906
J Clin Oncol. 1994 May;12(5):1058-62
pubmed: 8164030
Health Info Libr J. 2019 Sep;36(3):264-277
pubmed: 31328866
Leukemia. 2007 Apr;21(4):627-32
pubmed: 17252006
Jpn J Clin Oncol. 2009 Mar;39(3):163-8
pubmed: 19164318
J Natl Cancer Inst. 2013 Jul 17;105(14):1018-26
pubmed: 23860204
Semin Oncol. 1994 Apr;21(2 Suppl 3):21-8
pubmed: 8202722
Laryngorhinootologie. 2004 May;83(5):292-7
pubmed: 15143446
Blood. 1996 Apr 1;87(7):2675-82
pubmed: 8639883
J Clin Oncol. 2021 Mar 20;39(9):1001-1009
pubmed: 33439748
Leukemia. 2017 Sep;31(9):1944-1950
pubmed: 28626220
Ann Oncol. 2011 Sep;22(9):1988-1998
pubmed: 21385882
J Clin Oncol. 2016 Apr 10;34(11):1197-207
pubmed: 26858335
Eur J Cancer. 2005 Jul;41(11):1560-9
pubmed: 15953714
Clin Cancer Res. 2003 May;9(5):1689-97
pubmed: 12738722
Lancet. 2003 Oct 18;362(9392):1255-60
pubmed: 14575968
J Pain Symptom Manage. 2004 Feb;27(2):185-90
pubmed: 15157043
J Clin Oncol. 2008 Apr 1;26(10):1579-81
pubmed: 18375888
Arch Drug Inf. 2010 Sep;3(3):45-53
pubmed: 21331363
J Clin Oncol. 2011 Jan 1;29(1):97-105
pubmed: 21098317
Int J Clin Lab Res. 1998;28(2):127-34
pubmed: 9689556
Eur J Cancer. 2004 Oct;40(15):2293-306
pubmed: 15454256
BMC Cancer. 2009 Sep 03;9:311
pubmed: 19728887
J Clin Epidemiol. 1997 Jun;50(6):683-91
pubmed: 9250266
Mol Clin Oncol. 2016 Feb;4(2):211-220
pubmed: 26893865
Lancet Oncol. 2002 Aug;3(8):459-60
pubmed: 12147430
J Clin Epidemiol. 2006 Jan;59(1):7-10
pubmed: 16360555
Radiother Oncol. 2014 Jul;112(1):23-9
pubmed: 25129551
Int J Gynecol Cancer. 2008 May-Jun;18(3):515-24
pubmed: 17645506
Onkologie. 2013;36(5):266-72
pubmed: 23689221
Cochrane Database Syst Rev. 2022 Jun 20;6:CD012633
pubmed: 35724934
J Clin Oncol. 2002 May 15;20(10):2486-94
pubmed: 12011126
Support Care Cancer. 2017 Sep;25(9):2779-2786
pubmed: 28391437
Ann Hematol. 1995 Jun;70(6):313-8
pubmed: 7632811
Clin Breast Cancer. 2005 Feb;5(6):439-46
pubmed: 15748464
Am J Hematol. 2010 Sep;85(9):655-63
pubmed: 20661916
J Clin Oncol. 2001 Jun 1;19(11):2865-74
pubmed: 11387359
Anticancer Res. 2009 Feb;29(2):693-702
pubmed: 19331224
Arch Intern Med. 1995 Oct 23;155(19):2069-74
pubmed: 7575066
Crit Rev Oncol Hematol. 2003 Oct 15;48(Suppl):S49-55
pubmed: 14563521
Br J Cancer. 2003 Jun 16;88(12):1851-8
pubmed: 12799626
J Thorac Oncol. 2020 Feb;15(2):190-202
pubmed: 31629060
J Clin Oncol. 2005 Dec 20;23(36):9377-86
pubmed: 16361638
Clin Oncol (R Coll Radiol). 2008 Nov;20(9):705-13
pubmed: 18691854
J Clin Oncol. 2005 Apr 20;23(12):2597-605
pubmed: 15452188
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
Oncology (Williston Park). 2002 Sep;16(9 Suppl 10):117-24
pubmed: 12380961
J Clin Epidemiol. 2013 Feb;66(2):158-72
pubmed: 22609141
J Clin Oncol. 2008 Apr 1;26(10):1619-25
pubmed: 18375891
J Clin Oncol. 1995 Jul;13(7):1623-31
pubmed: 7602351
Front Radiat Ther Oncol. 2002;37:34-7
pubmed: 11764665
J Natl Cancer Inst. 1999 Oct 6;91(19):1616-34
pubmed: 10511589
Cancer. 1999 Oct 1;86(7):1362-7
pubmed: 10506726
Cancer. 2003 Jul 1;98(1):198-203
pubmed: 12833472
Acta Haematol. 1992;87 Suppl 1:4-11
pubmed: 1574966
Nephrol Dial Transplant. 2004 Jun;19(6):1571-5
pubmed: 15150356
Br J Haematol. 2001 Apr;113(1):172-9
pubmed: 11328297
Hematol Oncol. 2003 Dec;21(4):169-80
pubmed: 14735555
Ann Oncol. 2014 Jan;25(1):75-80
pubmed: 24356620
Lancet Oncol. 2003 Aug;4(8):459-60
pubmed: 12901958
J Pain Symptom Manage. 2006 Apr;31(4):317-25
pubmed: 16632079
J Support Oncol. 2005 Nov-Dec;3(6 Suppl 4):10-1
pubmed: 16355549
Anticancer Res. 2005 Sep-Oct;25(5):3495-500
pubmed: 16101168
J Clin Oncol. 2010 Nov 20;28(33):4996-5010
pubmed: 20975064
Med Oncol. 1998 Sep;15(3):174-82
pubmed: 9819794
Cochrane Database Syst Rev. 2009 Jul 08;(3):CD006158
pubmed: 19588382
J Clin Oncol. 2004 Apr 1;22(7):1301-7
pubmed: 15051778
J Clin Oncol. 2007 Mar 20;25(9):1027-32
pubmed: 17312332
Oncologist. 1996;1(3):140-150
pubmed: 10387980
Gynecol Oncol. 2008 Feb;108(2):317-25
pubmed: 18037478
Oncology. 2006;70(1):34-48
pubmed: 16493206
Nutr Cancer. 2018 Oct;70(7):1106-1117
pubmed: 30198775
Cancer. 2003 Nov 1;98(9):1786-801
pubmed: 14584059
BMJ. 2014 Sep 24;349:g5630
pubmed: 25252733
Acta Haematol. 1992;87 Suppl 1:12-5
pubmed: 1574960
J Clin Oncol. 2005 Sep 1;23(25):5960-72
pubmed: 16087945
Oncology (Williston Park). 2002 Oct;16(10 Suppl 11):45-55
pubmed: 12435173
Eur J Cancer. 2007 Jan;43(2):258-70
pubmed: 17182241
Br J Haematol. 1995 Mar;89(3):627-9
pubmed: 7734364
Curr Med Res Opin. 2009 Sep;25(9):2109-20
pubmed: 19601709
Transfusion. 1996 Feb;36(2):155-9
pubmed: 8614967
Int J Clin Oncol. 2001 Dec;6(6):296-301
pubmed: 11828949
J Clin Oncol. 2009 Feb 1;27(4):644-6
pubmed: 19103725
J Clin Oncol. 2008 May 10;26(14):2342-9
pubmed: 18467726
Qual Life Res. 2003 Dec;12(8):1013-27
pubmed: 14651419
Ann Oncol. 2006 Jan;17(1):146-50
pubmed: 16251202
Blood. 1995 Dec 15;86(12):4446-53
pubmed: 8541533
Res Synth Methods. 2012 Dec;3(4):312-24
pubmed: 26053424
Gynecol Oncol. 1997 Jun;65(3):461-6
pubmed: 9190976
J Natl Cancer Inst. 1993 May 19;85(10):801-6
pubmed: 8487324
Br J Haematol. 2003 Aug;122(3):394-403
pubmed: 12877666
Cancer J Sci Am. 1995 Nov-Dec;1(4):261-6
pubmed: 9166486
Am J Kidney Dis. 1992 Jul;20(1 Suppl 1):21-4
pubmed: 1626553
Arch Drug Inf. 2011 Sep;4(3):33-41
pubmed: 22022341
Arch Intern Med. 2008 Nov 24;168(21):2377-81
pubmed: 19029504
Blood. 2000 Feb 15;95(4):1175-9
pubmed: 10666187
Best Pract Res Clin Haematol. 2005 Jun;18(2):347-61
pubmed: 15737895
Nephrol Dial Transplant. 2006 Feb;21(2):378-82
pubmed: 16286429
J Natl Compr Canc Netw. 2012 May;10(5):628-53
pubmed: 22570293
J Natl Cancer Inst. 2006 May 17;98(10):708-14
pubmed: 16705125
J Pain Symptom Manage. 2003 Jun;25(6):512-8
pubmed: 12782431
JAMA. 2015 Nov 17;314(19):2062-8
pubmed: 26575062
Int J Radiat Oncol Biol Phys. 1993 Jul 15;26(4):721-9
pubmed: 8331011
BMC Med Res Methodol. 2015 Jul 31;15:58
pubmed: 26227148
Stat Med. 1998 Dec 30;17(24):2815-34
pubmed: 9921604
Br J Cancer. 1999 May;80(3-4):396-402
pubmed: 10408844
Support Care Cancer. 2004 Apr;12(4):253-62
pubmed: 14740283
Pharmacotherapy. 2016 Apr;36(4):402-14
pubmed: 26927900
Br J Cancer. 2006 Apr 10;94(7):947-54
pubmed: 16570051
Oncologist. 2008 Jun;13(6):715-24
pubmed: 18586927
J Clin Oncol. 2010 May 1;28(13):2239-45
pubmed: 20368566
Asia Pac J Clin Oncol. 2018 Apr;14(2):e129-e137
pubmed: 28849623
JAMA. 2008 Feb 27;299(8):914-24
pubmed: 18314434
J Clin Epidemiol. 2009 Oct;62(10):1006-12
pubmed: 19631508
J Natl Cancer Inst. 2002 Aug 21;94(16):1211-20
pubmed: 12189224
Semin Oncol. 2002 Jun;29(3 Suppl 8):55-9
pubmed: 12082655
PLoS One. 2013 Oct 03;8(10):e76654
pubmed: 24098547
Int J Radiat Oncol Biol Phys. 2007 Nov 15;69(4):1008-17
pubmed: 17716826
Gynecol Oncol. 2013 Dec;131(3):679-82
pubmed: 24099839
J Clin Oncol. 2008 Feb 1;26(4):592-8
pubmed: 18235117
Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):907-15
pubmed: 25670542
Br J Cancer. 2003 Apr 7;88(7):988-95
pubmed: 12671693
Support Cancer Ther. 2004 Oct 1;2(1):52-8
pubmed: 18628159